Amgen exits denosumab partnership

|About: Amgen Inc. (AMGN)|By:, SA News Editor

Amgen (AMGN -1.3%) ends its collaboration with Glaxo Group (GSK -0.9%) regarding the commercialization of denosumab for osteoporosis indications in certain geographies. The partnership began on July 27, 2009.

All commercial activities assigned to GSK other than those in Australia will transition back to AMGN by the end of the year.

In exchange for the early termination, AMGN will pay GSK $275M plus $15M in reimbursements for transition-related costs.